论文部分内容阅读
探讨重组人血管内皮抑素注射液(恩度,YH-16)联合化疗治疗多种晚期恶性肿瘤的疗效及不良反应。20例经病理或细胞学检查确诊的恶性肿瘤患者,采用恩度联合化疗治疗,将恩度15mg加入NS250mL或500mL中匀速静脉滴入,d1～d14,同时联合化疗。每21d为1个周期。20例患者中,仅1例肺癌患者因经济受限仅完成1个周期的联合治疗,其余19例均完成2～6个周期的治疗,周期数为48个,平均2.5个。19例可评价患者中,PR3例,SD14例,PD2例,RR15.8%(3/19),疾病控制率89.5%(17/19)。生活质量改善13例,稳定3例,下降3例。G3/4毒副反应,主要有3例骨髓抑制,恶心呕吐及腹泻各1例。初步研究结果提示,恩度与化疗联合可以显著提高患者生活质量,并可提高疗效,毒副反应没有增加。
To investigate the efficacy and adverse reactions of recombinant human endostatin injection (Endo, YH-16) in combination with chemotherapy for various advanced malignancies. Twenty patients with pathologically or cytologically diagnosed malignant tumors were treated with Endo combined with chemotherapy. Endostar 15mg was added to NS250mL or 500mL for uniform dosing, d1 to d14, and concurrent chemotherapy. Every 21d for a period. Of the 20 patients, only 1 patient with lung cancer completed only one cycle of combination therapy due to financial constraints, while the other 19 patients completed 2 to 6 cycles of treatment, with a cycle number of 48 and an average of 2.5 patients. Of the 19 evaluable patients, PR3, SD14, PD2, RR15.8% (3/19), and disease control rate 89.5% (17/19). Quality of life improved in 13 cases, stable in 3 cases, decreased in 3 cases. G3 / 4 toxicity, there are three cases of bone marrow suppression, nausea and vomiting and diarrhea in 1 case. Preliminary results suggest that, Endo and chemotherapy can significantly improve the quality of life of patients, and can improve the efficacy of toxic side effects did not increase.